RepliCel Life Sciences, Inc.: RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life Sciences Inc. (OTCPINK:REPCF) (TSXV:RP) (FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Akimichi Morita, one of Japan s leading dermatology research clinicians, has agreed to be RepliCel s clinical advisor for the development and commercialization of its skin rejuvenation product (RCS-01) in Japan.
The Company, working with industry leaders, CJ Partners, and clinical research organization, Accerise, is currently preparing to support the next-phase clinical research study of its skin rejuvenation cell therapy, RCS-01, in Japan under the Act for Safety of Regenerative Medicine (ASRM) that, upon successfully meeting its endpoints, could lead to a commercial launch of the product in Japan.
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Japan s Ministry of Health, Labour and Welfare Grants Priority Review for Enfortumab Vedotin New Drug Application
NDA, submitted in March, is for locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication
News provided by
Share this article
Share this article
TOKYO, May 13, 2021 /PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas ) today announced Japan s Ministry of Health, Labour and Welfare (MHLW) has granted priority review for the company s New Drug Application (NDA), which was submitted in March. If approved, enfortumab vedotin would be the first antibody-drug conjugate (ADC) available in Japan for the treatment of patients with locally advanced or metastatic urothelial cancer that has progressed after anti-cancer medication.
Рязанцу назначено 8 лет и 8 месяцев лишения свободы за убийство матери rv-ryazan.ru - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rv-ryazan.ru Daily Mail and Mail on Sunday newspapers.